Welcome to our dedicated page for Quanterix SEC filings (Ticker: QTRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to decode Quanterix’s R&D spend, grant revenue and Simoa roll-out plans inside a 200-page disclosure can slow any analyst. That’s why our platform keeps Quanterix SEC filings explained simply. Stock Titan’s AI pinpoints the assays driving growth and flags accounting nuances the moment each document hits EDGAR.
Need the numbers fast? Our dashboard links every Quanterix quarterly earnings report 10-Q filing to AI commentary on instrument placements and consumable margins, while a single click delivers a Quanterix annual report 10-K simplified summary that highlights R&D burn and royalty obligations. Form 8-K alerts—think FDA assay clearances—arrive under the heading Quanterix 8-K material events explained. Executive pay questions? Open the latest Quanterix proxy statement executive compensation note and see side-by-side trend charts.
Real-time compliance matters too. Track every Quanterix insider trading Form 4 transactions notice or set instant e-mail triggers for Quanterix Form 4 insider transactions real-time. Use our heat-map to spot cluster buying, then overlay it with Quanterix earnings report filing analysis for context. Whether you’re understanding Quanterix SEC documents with AI before a funding round or reviewing Quanterix executive stock transactions Form 4 ahead of board meetings, the platform supplies complete coverage—10-K, 10-Q, 8-K, Form 4, S-1 and more—updated the instant Quanterix uploads to EDGAR.
Portolan Capital Management, LLC and its manager George McCabe report beneficial ownership of 3,633,622 shares of Quanterix Corp common stock, representing 9.36% of the class, as disclosed on a Schedule 13G (Amendment No. 3). The filing shows sole voting and sole dispositive power over these shares and indicates Portolan acts in its capacity as a registered investment adviser while Mr. McCabe is identified as the manager with indirect interest.
The statement includes a certification that the securities were not acquired to change or influence control of the issuer, consistent with a passive 13G filing. No shared voting or dispositive powers are reported and no other holders are identified in this filing.
Quanterix Corporation is asking stockholders to vote at a virtual annual meeting at 9:00 a.m. ET on September 23, 2025. Holders of record as of July 31, 2025 may vote on six proposals, including the election of three directors (Myla Lai-Goldman, Masoud Toloue and David Walt), an advisory say-on-pay vote, ratification of KPMG LLP as auditor, and three Charter amendments to declassify the Board and remove supermajority vote requirements for certain Charter and Bylaws amendments.
The company completed the acquisition of Akoya Biosciences on July 8, 2025, which led to two Akoya directors joining Quanterix and two predecessors resigning. A Cooperation Agreement with activist holder Kent Lake was reached on August 4, 2025, which includes appointing one independent director by December 1, 2025 and seeking Board declassification. The Board recommends voting in favor of all proposals.
Quanterix Corporation (QTRX) filed Post-Effective Amendment No. 3 on Form S-8 to its previously declared-effective Form S-4, completing the technical step needed to register shares that will be issued under equity awards assumed from Akoya Biosciences following the recently closed merger.
- Shares registered: 253,181 shares of Quanterix common stock, representing the maximum issuable upon vesting of outstanding Akoya restricted stock units ("Rollover RSUs").
- Merger exchange ratio: each Akoya share converted at closing into 0.1470 Quanterix share plus $0.37 cash.
- Total shares previously registered: 8,357,169 on the original Form S-4, covering stock consideration to Akoya shareholders and all equity awards; today’s filing carves out only the RSU component.
- Fees: all SEC filing fees were paid with the original Form S-4; no additional fees are due.
- Plan coverage: the amendment relates to the Akoya Biosciences 2015 & 2021 Equity Incentive Plans, now assumed by Quanterix.
- Rule 416(a) applicability: automatic coverage for share increases from stock splits, dividends, or similar corporate actions.
Part II of the filing reiterates standard incorporation by reference of recent Quanterix periodic reports, describes Delaware law-based indemnification provisions, and lists exhibits, including opinions from Covington & Burling LLP and auditor consents. The document is strictly administrative—no new financial results, guidance, or strategic changes are disclosed; its primary purpose is to ensure that shares underlying assumed Akoya equity awards are properly registered for issuance post-merger.
FAQ
What is the current stock price of Quanterix (QTRX)?
What is the market cap of Quanterix (QTRX)?
